• Je něco špatně v tomto záznamu ?

In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia

M. Hüttl, I. Markova, D. Miklankova, I. Zapletalova, M. Poruba, M. Haluzik, I. Vaněčkova, H. Malinska

. 2021 ; 22 (21) : . [pub] 20211026

Jazyk angličtina Země Švýcarsko

Typ dokumentu časopisecké články

Perzistentní odkaz   https://www.medvik.cz/link/bmc22003418

Grantová podpora
19-06199S Czech Science Foundation
IGA_LF_2021_013 Ministry of Health of the Czech Republic

Recent studies suggest that treatment with SGLT-2 inhibitors can reduce hepatic lipid storage and ameliorate non-alcoholic fatty liver disease (NAFLD) development beyond their glycemic benefits. However, the exact mechanism involved is still unclear. We investigated the hepatic metabolic effect of empagliflozin (10 mg/kg/day for eight weeks) on the development of NAFLD and its complications using HHTg rats as a non-obese prediabetic rat model. Empagliflozin treatment reduced neutral triacylglycerols and lipotoxic diacylglycerols in the liver and was accompanied by significant changes in relative mRNA expression of lipogenic enzymes (Scd-1, Fas) and transcription factors (Srebp1, Pparγ). In addition, alterations in the gene expression of cytochrome P450 proteins, particularly Cyp2e1 and Cyp4a, together with increased Nrf2, contributed to the improvement of hepatic lipid metabolism after empagliflozin administration. Decreased circulating levels of fetuin-A improved lipid metabolism and attenuated insulin resistance in the liver and in peripheral tissues. Our results highlight the beneficial effect of empagliflozin on hepatic lipid metabolism and lipid accumulation independent of obesity, with the mechanisms understood to involve decreased lipogenesis, alterations in cytochrome P450 proteins, and decreased fetuin-A. These changes help to alleviate NAFLD symptoms in the early phase of the disease and before the onset of diabetes.

Citace poskytuje Crossref.org

000      
00000naa a2200000 a 4500
001      
bmc22003418
003      
CZ-PrNML
005      
20220127150244.0
007      
ta
008      
220113s2021 sz f 000 0|eng||
009      
AR
024    7_
$a 10.3390/ijms222111513 $2 doi
035    __
$a (PubMed)34768942
040    __
$a ABA008 $b cze $d ABA008 $e AACR2
041    0_
$a eng
044    __
$a sz
100    1_
$a Hüttl, Martina $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic
245    10
$a In a Prediabetic Model, Empagliflozin Improves Hepatic Lipid Metabolism Independently of Obesity and before Onset of Hyperglycemia / $c M. Hüttl, I. Markova, D. Miklankova, I. Zapletalova, M. Poruba, M. Haluzik, I. Vaněčkova, H. Malinska
520    9_
$a Recent studies suggest that treatment with SGLT-2 inhibitors can reduce hepatic lipid storage and ameliorate non-alcoholic fatty liver disease (NAFLD) development beyond their glycemic benefits. However, the exact mechanism involved is still unclear. We investigated the hepatic metabolic effect of empagliflozin (10 mg/kg/day for eight weeks) on the development of NAFLD and its complications using HHTg rats as a non-obese prediabetic rat model. Empagliflozin treatment reduced neutral triacylglycerols and lipotoxic diacylglycerols in the liver and was accompanied by significant changes in relative mRNA expression of lipogenic enzymes (Scd-1, Fas) and transcription factors (Srebp1, Pparγ). In addition, alterations in the gene expression of cytochrome P450 proteins, particularly Cyp2e1 and Cyp4a, together with increased Nrf2, contributed to the improvement of hepatic lipid metabolism after empagliflozin administration. Decreased circulating levels of fetuin-A improved lipid metabolism and attenuated insulin resistance in the liver and in peripheral tissues. Our results highlight the beneficial effect of empagliflozin on hepatic lipid metabolism and lipid accumulation independent of obesity, with the mechanisms understood to involve decreased lipogenesis, alterations in cytochrome P450 proteins, and decreased fetuin-A. These changes help to alleviate NAFLD symptoms in the early phase of the disease and before the onset of diabetes.
650    _2
$a zvířata $7 D000818
650    _2
$a benzhydrylové sloučeniny $x farmakologie $7 D001559
650    _2
$a systém (enzymů) cytochromů P-450 $x metabolismus $7 D003577
650    _2
$a modely nemocí na zvířatech $7 D004195
650    _2
$a progrese nemoci $7 D018450
650    _2
$a glukosidy $x farmakologie $7 D005960
650    _2
$a hyperglykemie $x farmakoterapie $x etiologie $x metabolismus $7 D006943
650    _2
$a hyperlipoproteinemie typ IV $x komplikace $x farmakoterapie $x metabolismus $7 D006953
650    _2
$a mediátory zánětu $x metabolismus $7 D018836
650    _2
$a inzulinová rezistence $7 D007333
650    _2
$a metabolismus lipidů $x účinky léků $7 D050356
650    _2
$a játra $x účinky léků $x metabolismus $7 D008099
650    _2
$a mužské pohlaví $7 D008297
650    _2
$a nealkoholová steatóza jater $x etiologie $x metabolismus $x prevence a kontrola $7 D065626
650    _2
$a obezita $x komplikace $x metabolismus $7 D009765
650    _2
$a oxidační stres $x účinky léků $7 D018384
650    _2
$a prediabetes $x komplikace $x farmakoterapie $x metabolismus $7 D011236
650    _2
$a krysa rodu Rattus $7 D051381
650    _2
$a mutantní kmeny potkanů $7 D011922
650    _2
$a potkani Wistar $7 D017208
650    _2
$a glifloziny $x farmakologie $7 D000077203
655    _2
$a časopisecké články $7 D016428
700    1_
$a Markova, Irena $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic
700    1_
$a Miklankova, Denisa $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic
700    1_
$a Zapletalova, Iveta $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
700    1_
$a Poruba, Martin $u Department of Pharmacology, Faculty of Medicine and Dentistry, Palacky University Olomouc, 77900 Olomouc, Czech Republic
700    1_
$a Haluzik, Martin $u Diabetes Centre, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic
700    1_
$a Vaněčkova, Ivana $u Department of Experimental Hypertension, Institute of Physiology, Czech Academy of Sciences, 14220 Prague, Czech Republic
700    1_
$a Malinska, Hana $u Centre for Experimental Medicine, Institute for Clinical and Experimental Medicine, 14321 Prague, Czech Republic
773    0_
$w MED00176142 $t International journal of molecular sciences $x 1422-0067 $g Roč. 22, č. 21 (2021)
856    41
$u https://pubmed.ncbi.nlm.nih.gov/34768942 $y Pubmed
910    __
$a ABA008 $b sig $c sign $y p $z 0
990    __
$a 20220113 $b ABA008
991    __
$a 20220127150240 $b ABA008
999    __
$a ok $b bmc $g 1751008 $s 1154567
BAS    __
$a 3
BAS    __
$a PreBMC
BMC    __
$a 2021 $b 22 $c 21 $e 20211026 $i 1422-0067 $m International journal of molecular sciences $n Int J Mol Sci $x MED00176142
GRA    __
$a 19-06199S $p Czech Science Foundation
GRA    __
$a IGA_LF_2021_013 $p Ministry of Health of the Czech Republic
LZP    __
$a Pubmed-20220113

Najít záznam

Citační ukazatele

Možnosti archivace